Logo

XDx Inks PGx Collaboration with Bristol-Myers for Lupus

Jan 09, 2009
NEW YORK (GenomeWeb News) – XDx said today that it has signed a pharmacogenomics pact with Bristol-Myers Squibb to identify biomarkers that would be used for diagnostic purposes in the development of a drug for systemic lupus erythematosus.
 
XDx is developing non-invasive, gene-expression tests for monitoring immune-mediated conditions. Bristol-Myers will make an upfront payment to XDx and additional milestone payments based on the achievement of specific R&D objectives. Brisbane, Calif.-based XDx also gets commercial rights to certain diagnostic applications that result from the collaboration.
 
The firms will be working on tests to monitor the effectiveness of Bristol-Myers’ rheumatoid arthritis drug abatacept (Orencia) in treating lupus.
 
Further terms of the collaboration were not disclosed.

Filed under

Diagnostics
Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.